Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
glycopyrronium bromide, Quantity: 63 microgram (Equivalent: glycopyrronium, Qty 50 microgram)
Novartis Pharmaceuticals Australia Pty Ltd
glycopyrronium bromide (glycopyrrolate)
Inhalation, powder for
Excipient Ingredients: hypromellose; carrageenan; potassium chloride; magnesium stearate; purified water; sunset yellow FCF; lactose monohydrate; strong ammonia solution; ethanol absolute; propylene glycol; potassium hydroxide; butan-1-ol; Shellac; iron oxide black; isopropyl alcohol
Inhalation
3 X (30 capsules + 1 device) = 90 capsules + 3 devices, 30 capsules+1 device, 10 capsules + 1 device (sample pack)
(S4) Prescription Only Medicine
SEEBRI BREEZHALER is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
Visual Identification: Transparent orange capsules containing a white powder with product code GPL50; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 18 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure
Registered
2012-11-12
SEEBRI ® BREEZHALER ® CAPSULES FOR INHALATION _Glycopyrronium bromide (glycopyrrolate)_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Seebri Breezhaler. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. The information in this leaflet was last updated on the date listed on the final page. More recent information on the medicine may be available. YOU SHOULD ENSURE THAT YOU SPEAK TO YOUR PHARMACIST OR DOCTOR TO OBTAIN THE MOST UP-TO-DATE INFORMATION ON THE MEDICINE. YOU CAN ALSO DOWNLOAD THE MOST UP-TO- DATE LEAFLET FROM WWW.NOVARTIS.COM.AU. Those updates may contain important information about the medicine and its use of which you should be aware. All medicines have risks and benefits. Your doctor has weighed the risks of you having Seebri Breezhaler against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT HAVING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT SEEBRI BREEZHALER IS USED FOR Seebri capsules are for the treatment of chronic obstructive pulmonary disease, also called COPD. COPD is a serious lung condition that can cause difficulty in breathing, and constant coughing. Symptoms of COPD include shortness of breath, cough, chest discomfort and coughing up phlegm. Seebri capsules for inhalation belong to a group of medicines called bronchodilators. These medicines are used to keep the air passages in the lungs open and make breathing easier. Seebri Breezhaler block tightening of these muscles in the lungs, making it easier for air to get in and out of the lungs. Seebri capsules for inhalation contain the active ingredient, glycopyrronium bromide (glycopyrrolate) in a capsule form. The capsules are for oral inhalation only. The powder from the capsule is inhaled (breathed into the lungs), using the Breezhaler ® inhalation device provided with the medicine. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS AB Read the complete document
1 AUSTRALIAN PI – SEEBRI BREEZHALER (GLYCOPYRRONIUM) POWDER FOR INHALATION IN CAPSULE 1 NAME OF THE MEDICINE _Glycopyrronium bromide is now known as glycopyrrolate. _ 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SEEBRI hard capsules are for oral inhalation only. SEEBRI is also supplied with a BREEZHALER inhalation device to permit oral inhalation of the contents of the capsule shell. Each capsule contains 63 microgram glycopyrronium bromide (glycopyrrolate) equivalent to 50 microgram glycopyrronium. The delivered dose (the dose that leaves the mouthpiece of the SEEBRI BREEZHALER inhaler) is equivalent to 44 microgram glycopyrronium. EXCIPIENTS: Lactose monohydrate For the full list of excipients, see Section 6.1 3 PHARMACEUTICAL FORM Inhalation powder, hard capsule Transparent orange capsules containing a white powder, with the product code GPL50 printed in black above a black bar and the company logo ( ) printed under a black bar. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS SEEBRI BREEZHALER is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). 4.2 D OSE AND METHOD OF ADMINISTRATION Dosage The recommended dosage of SEEBRI BREEZHALER is once-daily inhalation of the content of one 50 μg SEEBRI capsule using the BREEZHALER inhaler. Method of administration SEEBRI capsules must be administered only by the oral inhalation route and only using the BREEZHALER inhaler. SEEBRI capsules must not be swallowed. 2 SEEBRI BREEZHALER is recommended to be administered at the same time of the day each day. If a dose is missed, the missed dose should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day. SEEBRI capsules must always be stored in the blister to protect from moisture, and only removed IMMEDIATELY BEFORE USE. Patients who do not experience improvement in breathing should be asked if they are swallowing the medicine rather than inhaling it. When prescribing SEEBR Read the complete document